General
Preferred name
lisofylline
Synonyms
(R)-Lisofylline ()
(R)-Lisophylline ()
CT-1501R ()
Lisofylline, (r)- ()
CT 1501R ()
ProTec ()
P&D ID
PD021188
CAS
100324-81-0
Tags
drug candidate
natural product
available
Drug indication
Type-1 diabetes
Immunomodulator
Drug Status
investigational
Max Phase
Phase 2
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Lisophylline is an active metabolite of . The compound has novel anti-inflammatory properties, likely through inhibition of IL-12 signalling and STAT-4 activation . It is reported to prevent type 1 diabetes in preclinical models and improve the function and viability of isolated or transplanted pancreatic islets . Evidence suggests that combined treatment with lisofylline (for its anti-inflammatory action) and exendin-4 (to enhance beta-cell proliferation) can reverse autoimmune diabetes in the non-obese diabetic (NOD) mouse model . (GtoPdb)
DESCRIPTION LSF, a chiral metabolite of pentoxifylline, acts as a potent anti-inflammatory agent. (R)-LSF is the biologically active isomer of LSF. (BOC Sciences Bioactive Compounds)
Compound Sets
8
BOC Sciences Bioactive Compounds
r-lisofylline-cas-100324-81-0-item-262438
Cayman Chemical Bioactives
13616
ChEMBL Drugs
CHEMBL1411
Drug Repurposing Hub
DrugBank
DB12406
DrugMAP
DMVU9X1
Guide to Pharmacology
9225
MedChem Express Bioactive Compound Library
HY-109854A
External IDs
26
Properties
(calculated by RDKit )
Molecular Weight
280.15
Hydrogen Bond Acceptors
7
Hydrogen Bond Donors
1
Rotatable Bonds
5
Ring Count
2
Aromatic Ring Count
2
cLogP
-0.02
TPSA
82.05
Fraction CSP3
0.62
Chiral centers
1.0
Largest ring
6.0
QED
0.78
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
MOA
interleukin receptor antagonist, STAT inhibitor
Pathway
JAK/STAT Signaling
Stem Cell/Wnt
Target
STAT
Source data